
#ATA2026 is a wrap! We had an energizing few days in Philadelphia, sharing our genomic tests with thyroid experts from around the world. Many presentations featured our Afirma® GSC test and Veracyte GRID*, a research-use-only database. So, we wanted to say thank you and share a few highlights: 🔹 Cell Surface Proteins in Medullary #ThyroidCancer: Huge thanks to Sarah Hamidi, M.D., from the MD Anderson Cancer Center for presenting results from a retrospective cohort study evaluating expressed cell surface targets (CSTs) in consecutive Afirma Genomic Sequencing Classifier (GSC) tested thyroid nodules sent at the discretion of the ordering clinician from 2018-2024. Dr. Hamidi shared findings from a differential mRNA analysis of 78CSTs, showing that their mRNA expression could be readily detected in #ThyroidNodule FNA samples, including potentially actionable proteins overexpressed in medullary thyroid cancer-positive nodules. DLL3 and SSTR2 emerged as the most highly expressed potentially targetable CSTs, showing distinct associations with tumor genotype, correlating with RET and RAS mutational status, respectively. These results suggest that targeted therapeutic strategies against CSTs in advanced MTC are worthy of further investigation. 🔹 PSMA in #ThyroidNodules: We are also grateful to Wassim Najjar, M.D., and Prasanna Santhanam, M.D., from Johns Hopkins University, for sharing findings from a study exploring whether prostate-specific membrane antigen (PSMA) is associated with adverse pathologic features in thyroid nodules. Drs. Najjar and Santhanam and colleagues measured FOLH1 mRNA levelsderived from the Veracyte GRID Research Tool*, observing that higher PSMA expression was associated with increased vascular invasion and the presence of lymphatic invasion/involvement. These results suggest that PSMA percentile may correlate with more aggressive tumor behavior, and that PSMA may act as a potential imaging target in papillary thyroid cancer. 🔹 We would also like to thank Taylor Cavazos Ph.D., Nicholas Bambach M.S., Eisha Gupta M.D., Arti Bhan M.D., David Allen, M.D., Janevi June Rebernigg D.O., Justin Bauzon, M.D., Gilman Plitt, M.D., Ph.D., and Nathalie Silva De Morais, M.D., Ph.D., for presenting additional research featuring #AfirmaThyroid, as well as all other investigators, site teams, and participants whose contributions made all the research shared at ATA this year possible. 🔗 See where #TeamVeracyte is headed next! veracyte.com/company/events-… 🔗 Learn more about the Veracyte Diagnostics Platform - veracyte.com/innovation/vera… | Notes | *Veracyte Genomic Resource for Intelligent Discovery (GRID) is for research use only and is not intended to guide patient management. **This article contains forward-looking statements, which involve risks and uncertainties - veracyte.com/legal/cautionar…















